Vaxcyte, Inc.
PCVX
$30.68
-$1.62-5.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | 75.00M | 75.00M |
| Gross Profit | -- | -- | -- | -75.00M | -75.00M |
| SG&A Expenses | 116.24M | 105.68M | 92.90M | 81.87M | 74.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 709.11M | 635.87M | 569.55M | 604.05M | 577.16M |
| Operating Income | -709.11M | -635.87M | -569.55M | -604.05M | -577.16M |
| Income Before Tax | -547.50M | -509.63M | -463.93M | -507.65M | -497.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -547.50 | -509.63 | -463.93 | -507.65 | -497.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -547.50M | -509.63M | -463.93M | -507.65M | -497.19M |
| EBIT | -709.11M | -635.87M | -569.55M | -604.05M | -577.16M |
| EBITDA | -698.62M | -626.91M | -562.54M | -599.03M | -573.11M |
| EPS Basic | -4.11 | -3.98 | -3.80 | -4.55 | -4.62 |
| Normalized Basic EPS | -2.57 | -2.49 | -2.37 | -2.84 | -2.89 |
| EPS Diluted | -4.11 | -3.98 | -3.80 | -4.55 | -4.62 |
| Normalized Diluted EPS | -2.57 | -2.49 | -2.37 | -2.84 | -2.89 |
| Average Basic Shares Outstanding | 530.62M | 511.84M | 487.84M | 455.17M | 433.14M |
| Average Diluted Shares Outstanding | 530.62M | 511.84M | 487.84M | 455.17M | 433.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |